Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome: A Pilot Study

Journal of Pediatrics

Volumn 167, Issue 6, 2015, Pages 1214-1220.e3

  Wiles, Jason R ^a   Isemann, Barbara ^b   Mizuno, Tomoyuki ^a   Tabangin, Meredith E ^a   Ward, Laura P ^a,c   Akinbi, Henry ^a,c   Vinks, Alexander A ^a,c  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE; NARCOTIC ANALGESIC AGENT;

BIOLOGICAL MODEL; CLINICAL TRIAL; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NEONATAL ABSTINENCE SYNDROME; NEWBORN; PILOT STUDY;

ANALGESICS, OPIOID; CHROMATOGRAPHY, LIQUID; HUMANS; INFANT, NEWBORN; MASS SPECTROMETRY; METHADONE; MODELS, BIOLOGICAL; NEONATAL ABSTINENCE SYNDROME; PILOT PROJECTS;

EID: 85027942807     PISSN: 00223476     EISSN: 10976833     Source Type: Journal    
DOI: 10.1016/j.jpeds.2015.08.032     Document Type: Article

References (36)

1. Hudak, M.L., Tan, R.C., Neonatal drug withdrawal. Pediatrics 129 (2012), e540–e560.
2. Kraft, W.K., van den Anker, J.N., Pharmacologic management of the opioid neonatal abstinence syndrome. Pediatr Clin North Am 59 (2012), 1147–1165.
3. Wiles, J.R., Isemann, B., Ward, L.P., Vinks, A.A., Akinbi, H., Current management of neonatal abstinence syndrome secondary to intrauterine opioid exposure. J Pediatr 165 (2014), 440–446.
4. Hayes, M.J., Brown, M.S., Epidemic of prescription opiate abuse and neonatal abstinence. JAMA 307 (2012), 1974–1975.
5. Paulozzi, L.J., Xi, Y., Recent changes in drug poisoning mortality in the United States by urban-rural status and by drug type. Pharmacoepidemiol Drug Saf 17 (2008), 997–1005.
6. Kellogg, A., Rose, C.H., Harms, R.H., Watson, W.J., Current trends in narcotic use in pregnancy and neonatal outcomes. Am J Obstet Gynecol 204 (2011), 259.e1–259.e4.
7. Patrick, S.W., Schumacher, R.E., Benneyworth, B.D., Krans, E.E., McAllister, J.M., Davis, M.M., Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA 307 (2012), 1934–1940.
8. Paulozzi, L.J., Mack, K.A., Hockenberry, J.M., Vital signs: variation among states in prescribing of opioid pain relievers and benzodiazepines—United States, 2012. MMWR Morb Mortal Wkly Rep 63 (2014), 563–568.
9. Epstein, R.A., Bobo, W.V., Martin, P.R., Morrow, J.A., Wang, W., Chandrasekhar, R., et al. Increasing pregnancy-related use of prescribed opioid analgesics. Ann Epidemiol 23 (2013), 498–503.
10. Patrick, S.W., Dudley, J., Martin, P.R., Harrell, F.E., Warren, M.D., Hartmann, K.E., et al. Prescription opioid epidemic and infant outcomes. Pediatrics 135 (2015), 842–850.
11. Patrick, S.W., Davis, M.M., Lehman, C.U., Cooper, W.O., Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol 35 (2015), 650–655.
12. Jones, H.E., Kaltenbach, K., Heil, S.H., Stine, S.M., Coyle, M.G., Arria, A.M., et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 363 (2010), 2320–2331.
13. Jansson, L., Velez, M., Harrow, C., The opioid exposed newborn: assessment and pharmacologic management. J Opioid Manag 5 (2009), 47–55.
14. Grim, K., Harrison, T., Wilder, R., Management of neonatal abstinence syndrome from opioids. Clin Perinatol 40 (2013), 509–524.
15. Sarkar, S., Donn, S.M., Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. J Perinatol 26 (2006), 15–17.
16. Hall, E.S., Wexelblatt, S.L., Crowley, M., Grow, J.L., Jasin, L.R., Klebanoff, M.A., et al. A Multicenter cohort study of treatments and hospital outcomes in neonatal abstinence syndrome. Pediatrics 134 (2014), e527–e534.
17. Patrick, S.W., Kaplan, H.C., Passarella, M., Davis, M.M., Variation in treatment of neonatal abstinence syndrome in US Children's Hospitals, 2004-2011. J Perinatol 34 (2014), 867–872.
18. Brown, M.S., Hayes, M.J., Thornton, L.M., Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. J Perinatol 35 (2015), 278–283.
19. Wiles, J.R., Vinks, A.A., Akinbi, H., Federal legislation and the advancement of neonatal drug studies. J Pediatr 162 (2013), 12–15.
20. Foster, D.J., Somogyi, A.A., White, J.M., Bochner, F., Population pharmacokinetics of (R)-, (S)-, and rac-methadone in methadone maintenance patients. Br J Clin Pharmacol 57 (2004), 742–755.
21. Stemland, C.J., Witte, J., Colquhoun, D.A., Durieux, M.E., Langman, L.J., Balireddy, R., et al. The pharmacokinetics of methadone in adolescents undergoing posterior spinal fusion. Paediatr Anaesth 23 (2013), 51–57.
22. Ward, R.M., Drover, D.R., Hammer, G.B., Stemland, C.J., Kern, S., Tristani-Firouzi, M., et al. The pharmacokinetics of methadone and its metabolites in neonates, infants, and children. Pediatr Anesth 24 (2014), 591–601.
23. Lucas, K., Knobel, R.B., Implementing practice guidelines and education to improve care of infants with neonatal abstinence syndrome. Adv Neonatal Care 12 (2012), 40–45.
24. Clavijo, C.F., Hoffman, K.L., Thomas, J.J., Carvalho, B., Chu, L.F., Drover, D.R., et al. A sensitive assay for the quantification of morphine and its active metabolites in human plasma and dried blood spots using high-performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 400 (2011), 715–728.
25. Clavijo, C.F., Thomas, J.J., Cromie, M., Schniedewind, B., Hoffman, K.L., Christians, W., et al. A low blood volume LC-MS/MS assay for the quantification of fentanyl and its major metabolites norfentanyl and despropionyl fentanyl in children. J Sep Sci 34 (2011), 3568–3577.
26. Taylor, R.R., Hoffman, K.L., Schniedewind, B., Clavijo, C., Galinkin, J.L., Christians, U., Comparison of the quantification of acetaminophen in plasma, cerebrospinal fluid and dried blood spots using high-performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 83 (2013), 1–9.
27. Fredheim, O., Moksnes, K., Borchgrevink, P., Kaasa, S., Dale, O., Clinical pharmacology of methadone for pain. Acta Anaesthesiol Scand 52 (2008), 879–889.
28. Yang, F., Tong, X., McCarver, D.G., Hines, R.N., Beard, D.A., Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model. J Pharmacokinet Pharmacodyn 33 (2006), 485–518.
29. Wang, Y., Jadhav, P.R., Lala, M., Gobburu, J.V., Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies. J Clin Pharmacol 52 (2012), 1601–1606.
30. Mould, D.R., Upton, R.N., Basic concepts in population modeling, simulation and model-based drug development. CPT Pharmacometrics Syst Pharmacol, 1, 2012, e6.
31. Rostami-Hodjegan, A., Wolff, K., Hay, A.W., Raistrick, D., Calvert, R., Tucker, G.T., Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br J Clin Pharmacol 48 (1999), 43–52.
32. Neely, M., Jelliffe, R., Practical, individualized dosing: 21st century therapeutics and the clinical pharmacometrician. J Clin Pharmacol 50 (2010), 842–847.
33. Anderson, B.J., Holford, N.H., Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48 (2008), 303–332.
34. Anderson, B.J., Holford, N.H., Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 24 (2009), 25–36.
35. Ette, E.I., Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 37 (1997), 486–495.
36. Keizer, R.J., Karlsson, M.O., Hooker, A., Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN and Xpose. CPT Pharmacometrics Syst Pharmacol, 2, 2013, e50.